---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-100072"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T19:04:16.696946+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CFO Sung Lee resigns effective May 3; board nominates two new independent directors

## Summary
- CFO Sung Lee resigns effective May 3, 2024, to pursue other opportunity; no disagreement with company.
- Board nominates Norbert Bischofberger and Ramy Farid as independent director candidates for May 29 annual meeting.
- Founders Phillip Sharp and Robert Perez will not stand for reelection at the annual meeting.
- Bischofberger brings 40 years biotech experience (former Gilead R&D head); Farid is CEO of Schrödinger.

## SEC filing metadata
- accession: 0001193125-24-100072
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312524100072/0001193125-24-100072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312524100072/d824543d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-100072
- JSON: https://secwatch.observer/filing/0001193125-24-100072.json
- Plain text: https://secwatch.observer/filing/0001193125-24-100072.txt

## Key facts
- Executive change
  Sung Lee resigned as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
  - Action: resigned
  - Role: Executive Vice President and Chief Financial Officer
  source text: On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312524100072/0001193125-24-100072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.